康美药业：上半年净利润1690.14万元，同比增长7.24%

Core Viewpoint - Kangmei Pharmaceutical (600518) reported its semi-annual results on August 29, 2023, showing a modest growth in revenue and net profit for the first half of 2025 [1] Financial Performance - The company achieved an operating revenue of 2.577 billion yuan, representing a year-on-year increase of 4.17% [1] - The net profit attributable to shareholders of the listed company was 16.9014 million yuan, reflecting a year-on-year growth of 7.24% [1] - Basic earnings per share stood at 0.001 yuan [1]